Shkreli Jury Ends Third Day of Deliberations Without a Verdict

  • Retrophin co-founder accused of misusing investors’ funds
  • Jurors sent no notes during full day of talks on Wednesday

Why Martin Shkreli Is on Trial for Making Millions

The jury mulling the fate of Retrophin Inc. co-founder Martin Shkreli ended the third day of deliberations without a peep.

On Tuesday, the panel had asked for the definitions of "assets under management" and "fraudulent intent," but it didn’t communicate with the court on Wednesday.

The 34-year-old Shkreli, known as "Pharma Bro," is accused of taking money from investors in his previous hedge funds and using it to start Retrophin, then using the drug-development company’s cash to pay them back. He faces as long as 20 years in prison if convicted of the most serious charges against him.

The case is U.S. v. Shkreli, 15-cr-0637, U.S. District Court, Eastern District of New York (Brooklyn).

    Before it's here, it's on the Bloomberg Terminal.